Literature DB >> 7571183

Prostate cancer-induced oncogenic hypophosphatemic osteomalacia.

H Nakahama1, T Nakanishi, H Uno, T Takaoka, N Taji, O Uyama, O Kitada, M Sugita, A Miyauchi, T Sugishita.   

Abstract

A 65-year-old male with prostate carcinoma showed mild hypocalcemia of 7.9 mg/dl, marked hypophosphatemia of 1.7 mg/dl, hyperphosphaturia (tubular reabsorption of phosphorus 43% and tubular threshold for phosphorus of 0.6 mg/dl), low serum 1,25 (OH)2D level of less than 5 pg/ml and osteomalacia indicated by a marked increase of relative osteoid volume and fractional formation rate in the undecalcified section. Oncogenic osteomalacia due to prostatic carcinoma with suppression of 1,25 (OH)2D production and phosphaturia was suggested.

Entities:  

Mesh:

Year:  1995        PMID: 7571183     DOI: 10.1159/000282746

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  14 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

2.  Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia.

Authors:  Q L Huang; D S Feig; M E Blackstein
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

3.  Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

6.  ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Yuichi Takashi; Nobuaki Ito; Seiji Fukumoto; Masashi Fukuyama
Journal:  Med Mol Morphol       Date:  2015-06-30       Impact factor: 2.309

Review 7.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

8.  CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.

Authors:  David E Leaf; Renata C Pereira; Hasan Bazari; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

10.  Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.

Authors:  Nobuaki Ito; Takuo Kubota; Sachiko Kitanaka; Ikuma Fujiwara; Masanori Adachi; Yasuhiro Takeuchi; Hitomi Yamagami; Takehide Kimura; Tatsuya Shinoda; Masanori Minagawa; Ryo Okazaki; Keiichi Ozono; Yoshiki Seino; Seiji Fukumoto
Journal:  J Bone Miner Metab       Date:  2021-07-13       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.